Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.495 EUR
−55.85 M EUR
29.95 M EUR
61.06 M
About AC Immune SA
Sector
Industry
CEO
Andrea Pfeifer
Website
Headquarters
Lausanne
Founded
2003
ISIN
CH0329023102
FIGI
BBG00DY40R96
AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.
Related stocks
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange AC Immune SA stocks are traded under the ticker IMR.
We've gathered analysts' opinions on AC Immune SA future price: according to them, IMR price has a max estimate of 10.36 EUR and a min estimate of 6.82 EUR. Watch IMR chart and read a more detailed AC Immune SA stock forecast: see what analysts think of AC Immune SA and suggest that you do with its stocks.
Yes, you can track AC Immune SA financials in yearly and quarterly reports right on TradingView.
AC Immune SA is going to release the next earnings report on Nov 14, 2025. Keep track of upcoming events with our Earnings Calendar.
IMR earnings for the last quarter are −0.22 EUR per share, whereas the estimation was −0.22 EUR resulting in a 0.00% surprise. The estimated earnings for the next quarter are −0.20 EUR per share. See more details about AC Immune SA earnings.
AC Immune SA revenue for the last quarter amounts to 1.40 M EUR, despite the estimated figure of 1.40 M EUR. In the next quarter, revenue is expected to reach 863.75 K EUR.
IMR net income for the last quarter is −21.78 M EUR, while the quarter before that showed −19.57 M EUR of net income which accounts for −11.30% change. Track more AC Immune SA financial stats to get the full picture.
No, IMR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 26, 2025, the company has 172 employees. See our rating of the largest employees — is AC Immune SA on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. AC Immune SA EBITDA is −46.92 M EUR, and current EBITDA margin is −184.40%. See more stats in AC Immune SA financial statements.
Like other stocks, IMR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade AC Immune SA stock right from TradingView charts — choose your broker and connect to your account.